Log In
BCIQ
Print this Print this
 

IK-7002

  Manage Alerts
Collapse Summary General Information
Company Bellerophon Therapeutics Inc.
DescriptionInhaled nitric oxide (NO) delivered with the INOpulse DS drug-delivery system
Molecular Target NAD(P)H dehydrogenase quinone 1 (NQO1) (QR1)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHypertension
Indication DetailsTreat pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/01/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today